↓ Skip to main content

Epcoritamab induces potent anti-tumor activity against malignant B-cells from patients with DLBCL, FL and MCL, irrespective of prior CD20 monoclonal antibody treatment

Overview of attention for article published in Blood Cancer Journal, February 2021
Altmetric Badge

About this Attention Score

  • In the top 25% of all research outputs scored by Altmetric
  • Good Attention Score compared to outputs of the same age (77th percentile)
  • Above-average Attention Score compared to outputs of the same age and source (60th percentile)

Mentioned by

twitter
13 tweeters

Citations

dimensions_citation
6 Dimensions

Readers on

mendeley
10 Mendeley
Title
Epcoritamab induces potent anti-tumor activity against malignant B-cells from patients with DLBCL, FL and MCL, irrespective of prior CD20 monoclonal antibody treatment
Published in
Blood Cancer Journal, February 2021
DOI 10.1038/s41408-021-00430-6
Pubmed ID
Authors

Hilma J. van der Horst, A. Vera de Jonge, Ida H. Hiemstra, Anne T. Gelderloos, Daniella R. A. I. Berry, Nathalie J. Hijmering, Hendrik F. van Essen, Daphne de Jong, Martine E. D. Chamuleau, Sonja Zweegman, Esther C. W. Breij, Margaretha G. M. Roemer, Tuna Mutis

Twitter Demographics

The data shown below were collected from the profiles of 13 tweeters who shared this research output. Click here to find out more about how the information was compiled.

Mendeley readers

The data shown below were compiled from readership statistics for 10 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 10 100%

Demographic breakdown

Readers by professional status Count As %
Other 4 40%
Researcher 2 20%
Student > Doctoral Student 1 10%
Student > Bachelor 1 10%
Professor 1 10%
Other 1 10%
Readers by discipline Count As %
Medicine and Dentistry 5 50%
Biochemistry, Genetics and Molecular Biology 2 20%
Immunology and Microbiology 1 10%
Unspecified 1 10%
Unknown 1 10%

Attention Score in Context

This research output has an Altmetric Attention Score of 9. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 08 March 2021.
All research outputs
#2,890,963
of 17,896,489 outputs
Outputs from Blood Cancer Journal
#224
of 833 outputs
Outputs of similar age
#69,537
of 304,892 outputs
Outputs of similar age from Blood Cancer Journal
#22
of 58 outputs
Altmetric has tracked 17,896,489 research outputs across all sources so far. Compared to these this one has done well and is in the 83rd percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 833 research outputs from this source. They typically receive more attention than average, with a mean Attention Score of 9.5. This one has gotten more attention than average, scoring higher than 72% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 304,892 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 77% of its contemporaries.
We're also able to compare this research output to 58 others from the same source and published within six weeks on either side of this one. This one has gotten more attention than average, scoring higher than 60% of its contemporaries.